{"id":"NCT04432831","sponsor":"Hoffmann-La Roche","briefTitle":"A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema","officialTitle":"A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients With Diabetic Macular Edema","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-08-05","primaryCompletion":"2023-10-11","completion":"2023-10-11","firstPosted":"2020-06-16","resultsPosted":"2024-10-30","lastUpdate":"2024-10-30"},"enrollment":1479,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetic Macular Edema"],"interventions":[{"type":"DRUG","name":"Faricimab","otherNames":["RO6867461","RG7716"]},{"type":"OTHER","name":"Sham Procedure","otherNames":[]}],"arms":[{"label":"Faricimab PTI","type":"EXPERIMENTAL"}],"summary":"This is a multicenter long-term extension study designed to evaluate the long-term safety and tolerability of faricimab administered by intravitreal (IVT) injection at a personalized treatment interval (PTI) to participants who enrolled in and completed one of the two Phase III studies, GR40349 (NCT03622580) or GR40398 (NCT03622593), also referred to as the parent studies.","primaryOutcome":{"measure":"Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading Scale","timeFrame":"From the day of the first dose of faricimab until the end of the study (up to 108 weeks)","effectByArm":[{"arm":"Faricimab PTI (Prior Faricimab Q8W)","deltaMin":219,"sd":null},{"arm":"Faricimab PTI (Prior Faricimab PTI)","deltaMin":188,"sd":null},{"arm":"Faricimab PTI (Prior Aflibercept Q8W)","deltaMin":197,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":318,"countries":["United States","Argentina","Australia","Austria","Brazil","Bulgaria","Canada","Czechia","Denmark","France","Germany","Hong Kong","Hungary","Israel","Italy","Japan","Mexico","Peru","Poland","Portugal","Russia","Singapore","Slovakia","South Korea","Spain","Switzerland","Taiwan","Thailand","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":158,"n":491},"commonTop":["Cataract","COVID-19","Cataract","Diabetic retinal oedema","Hypertension"]}}